

Bölüm 19

NÜKS VE METASTATİK OVER KANSERİNDE SİSTEMİK TEDAVİ

Yasin SEZGİN¹

GİRİŞ

İleri evre over kanserli hastalarda, optimal cerrahi ve adjuvan kemoterapiye rağmen hastalık nüks edebilmektedir. İlk tedavi sonrası hangi hastada nüks gelişeceğini tam olarak gösteren bir parametre olmamakla birlikte, tanı anında hastalığın evresi, CA 125 seviyesi, yapılan cerrahinin başarısı ve verilen kemoterapiden alınan yanıt nüksü öngörmede bilgi verebilir.

Nüks veya metastatik over kanserinde, kemoterapi rejimi seçiminde platin direncinin olup olmadığı önem arz etmektedir. Herhangi bir platin tedavisinden sonraki ilk altı ay içinde nüks gelişmiş hastalarda platin direncinden bahsedilir. Platin tedavisinden altı ay sonra gelişen nükslerde ise hastalık platin duyarlı olarak kabul edilir. Over kanseri nüksleri; platin dirençli ve platin duyarlı olarak ikiye ayrılabilir. Burada nüks over kanseri; platin duyarlı ve platin dirençli nüks-metastatik over kanseri tedavisi şeklinde incelenecektir.

PLATİN DUYARLI NÜKS VEYA METASTATİK OVER KANSERİ

Over kanseri hastalarında herhangi bir platin tedavisi sonrası, 6 aydan uzun süre sonra nüks olması durumunda platin duyarlılığından bahsedilir. İki yüz on beş hastanın incelendiği MITO 8 çalışmasında platin tedavisinden 6-12 ay sonra nüks etmiş hastalar incelenmiş. Platin duyarlı olan hastaların bir kısmına platin içeren tedavi rejimleri verilirken, hastaların bir kısmına da platin içermeyen tedaviler verilmiştir. Bu çalışmanın sonucunda platin içeren grupta progresyonsuz sağkalım (PFS) 9.0 ay iken, platin içermeyen grupta 5.0 ay idi. Genel sağkalım (OS); platin içeren kolda 24.5 ay iken, platin içermeyen kolda 21.8 ay olup istatistiksel olarak anlamlı değildi [1].

¹ Uzman Dr.Yasin SEZGİN, Dicle Üniversitesi Tıp Fakültesi Onkoloji B.D, dr.yasin1982@hotmail.com

terapi tedavi için adaydır. Kontrendike bir durumu yok ise kombine kemoterapi tedavisine bevacizumab eklenmesi önerilir. Performans durumu kombine tedaviye uygun olmayan hastalara tekli ajan kemoterapi önerilir.

Platin dirençli nüks over kanserli hastalarda kombine tedavilerin tekli ajan kemoterapi tedavilerine üstünlüğü yoktur. Bu nedenle platin dirençli nüks over kanserli hastalarda tekli ajan kemoterapisi önerilir. Hasta daha önce taksan almamış ise öncelikle önerilen kemoterapi rejimi haftalık paklitakseldir. Platin dirençli over kanserli hastalarda tekli ajan kemoterapisine bevacizumab eklendiği zaman hastalarda alınan cevap ve progresyonsuz sağkalım oranları artmaktadır.

KAYNAKLAR

1. Pignata S, Scambia G, Bologna A, et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. *J Clin Oncol* 2017; 35:3347.
2. Cantù MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. *J Clin Oncol* 2002; 20:1232.
3. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. *J Clin Oncol* 1991; 9:389.
4. Zanaboni F, Scarfone G, Presti M, et al. Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide. *Gynecol Oncol* 1991; 43:24.
5. Ferrandina G, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. *Ann Oncol* 2007; 18:1348.
6. van der Burg ME, Hoff AM, van Lent M, et al. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. *Eur J Cancer* 1991; 27:248.
7. Weiss G, Green S, Alberts DS, et al. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. *Eur J Cancer* 1991; 27:135.
8. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. *J Clin Oncol* 1998; 16:1494.
9. Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. *Gynecol Oncol* 2009; 115:377.
10. Pignata S, Scambia G, Raspagliesi R, et al. The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. *J Clin Oncol* 2016; 34S: ASCO #5505.
11. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003; 361:2099.
12. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol* 2006; 24:4699.
13. Lawrie TA, Bryant A, Cameron A, et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. *Cochrane Database Syst Rev* 2013; :CD006910.

14. Bozas G, Bamias A, Koutsoukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. *Gynecol Oncol* 2007; 104:580.
15. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol* 2010; 28:3323.
16. Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. *Gynecol Oncol* 2011; 122:226.
17. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. *Br J Cancer* 2012; 107:588.
18. Gibson JM, Alzghari S, Ahn C, et al. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. *Oncologist* 2013; 18:1022.
19. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 1998; 16:405.
20. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. *J Clin Oncol* 2001; 19:3312.
21. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. *J Clin Oncol* 2008; 26:890.
22. Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. *Gynecol Oncol* 2015; 139:10.
23. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol* 2012; 30:2039.
24. Aghajanian C, Goff B, Nycum LR, et al. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. *Gynecol Oncol* 2014; 133:105.
25. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017; 18:779.
26. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125085s317lbl.pdf.
27. McGee J, Bookman M, Harter P, et al. Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. *Ann Oncol* 2017; 28:702.
28. Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. *Ann Oncol* 2012; 23:2605.
29. Peng LH, Chen XY, Wu TX. Topotecan for ovarian cancer. *Cochrane Database Syst Rev* 2008; :CD005589.
30. Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. *Am J Obstet Gynecol* 1994; 170:1666.
31. Gore ME, Levy V, Rustin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. *Br J Cancer* 1995; 72:1016.
32. Bruzzone M, Catsafados E, Miglietta L, et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. *Oncology* 1996; 53:349.
33. Ezcurdia L, Jovtis SL, Mickiewicz E, et al. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group. *Semin Oncol* 1997; 24:S15.

34. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. *Gynecol Oncol* 2004; 95:1.
35. Lorusso D, Naldini A, Testa A, et al. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? *Oncology* 2004; 67:243.
36. Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. *Gynecol Oncol* 2001; 82:323.
37. Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m²) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. *Gynecol Oncol* 2000; 78:369.
38. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. *J Clin Oncol* 2007; 25:2811.
39. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. *J Clin Oncol* 2000; 18:2733.
40. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2011; 122:111.
41. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. *J Clin Oncol* 2009; 27:2686.
42. Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. *Eur J Cancer* 2009; 45:1415.
43. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. *J Clin Oncol* 2014; 32:1302.
44. Poveda AM, Selle F, Hilpert F, et al. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. *J Clin Oncol* 2015; 33:3836.
45. Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). *Ann Oncol* 2012; 23:346.
46. Williams CJ. Tamoxifen for relapse of ovarian cancer. *Cochrane Database Syst Rev* 2001; :CD001034.
47. Lindemann K, Gibbs E, Åvall-Lundqvist E, et al. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). *Br J Cancer* 2017; 116:455.